ATE554389T1 - Apex als marker für lungenkrebs - Google Patents

Apex als marker für lungenkrebs

Info

Publication number
ATE554389T1
ATE554389T1 AT08716640T AT08716640T ATE554389T1 AT E554389 T1 ATE554389 T1 AT E554389T1 AT 08716640 T AT08716640 T AT 08716640T AT 08716640 T AT08716640 T AT 08716640T AT E554389 T1 ATE554389 T1 AT E554389T1
Authority
AT
Austria
Prior art keywords
lung cancer
apex
marker
assessment
relates
Prior art date
Application number
AT08716640T
Other languages
English (en)
Inventor
Marie-Luise Hagmann
Johann Karl
Julia Kloeckner
Markus Roessler
Michael Tacke
Michael Thierolf
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE554389T1 publication Critical patent/ATE554389T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT08716640T 2007-03-23 2008-03-19 Apex als marker für lungenkrebs ATE554389T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07006079 2007-03-23
PCT/EP2008/002224 WO2008116592A1 (en) 2007-03-23 2008-03-19 Apex as a marker for lung cancer

Publications (1)

Publication Number Publication Date
ATE554389T1 true ATE554389T1 (de) 2012-05-15

Family

ID=38480598

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08716640T ATE554389T1 (de) 2007-03-23 2008-03-19 Apex als marker für lungenkrebs

Country Status (8)

Country Link
US (1) US20110097756A1 (de)
EP (1) EP2130048B1 (de)
JP (1) JP5079023B2 (de)
CN (1) CN101641599A (de)
AT (1) ATE554389T1 (de)
CA (1) CA2681577A1 (de)
ES (1) ES2384125T3 (de)
WO (1) WO2008116592A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2569531A1 (en) 2004-06-04 2005-12-15 Aviaradx, Inc. Gene expression analysis for identification of tumor types
US20120258442A1 (en) * 2011-04-09 2012-10-11 bio Theranostics, Inc. Determining tumor origin
WO2006132971A2 (en) 2005-06-03 2006-12-14 Aviaradx, Inc. Identification of tumors and tissues
CA2742286C (en) * 2008-11-12 2016-08-09 F. Hoffmann-La Roche Ag Pacap as a marker for cancer
ES2493069T3 (es) 2009-05-15 2014-09-11 F. Hoffmann-La Roche Ag CYBP como marcador del cáncer de pulmón
JP5731488B2 (ja) * 2009-05-29 2015-06-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 癌のマーカーとしてのセセルニン‐１
CN101930004A (zh) * 2009-06-24 2010-12-29 中国科学院上海生命科学研究院 Apex1用作检测肝细胞癌的蛋白质分子标记的应用
KR101251222B1 (ko) * 2010-12-08 2013-04-08 충남대학교산학협력단 ＡＰＥ1/Ｒｅｆ-1을 함유하는 방광암 진단용 조성물, 및 이를 이용한 방광암 진단 키트
CA2826811A1 (en) * 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Apex1 as marker for chronic obstructive pulmonary disease (copd)
CN102507951B (zh) * 2011-11-25 2014-11-19 广东药学院 一种联合检测肿瘤标志物的酶联免疫检测试剂盒
CN102435748B (zh) * 2011-11-25 2014-07-16 广东药学院 一种双抗夹心酶联免疫检测试剂盒及其制备方法
EP3000088A4 (de) * 2013-05-23 2018-06-27 Iphenotype LLC Verfahren und system zur bewahrung oder verbesserung des wohlbefindens
CN105891482B (zh) * 2016-03-29 2017-12-19 复旦大学附属中山医院 一种基于生物标志物谱针对中国农村人口肺结节人群的肺癌风险预测模型
CN109406782A (zh) * 2016-05-11 2019-03-01 卢氏实验室公司 一种快速诊断和监控肺癌的免疫层析检测条及其制备方法
CN106053816B (zh) * 2016-08-19 2018-01-05 四川大学华西第二医院 肺癌诊断试剂盒
CN106645722B (zh) * 2016-10-17 2018-09-04 四川大学华西第二医院 一种肺癌筛查试剂盒
CN107860852A (zh) * 2017-11-23 2018-03-30 南宁科城汇信息科技有限公司 一种基于iTRAQ联合LC、MALDI的差异蛋白组学

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919643A (en) * 1996-06-11 1999-07-06 Advanced Research & Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
WO2000038715A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of an integrin antagonist and radiation in the treatment of neoplasia
EP1430145B1 (de) * 2001-03-23 2013-01-02 Yeda Research And Development Co., Ltd. Verfahren zur bestimmung eines risikos, an krebs zu erkranken, zur beurteilung einer wirksamkeit und dosierung einer krebstherapie und zur korrelation zwischen einer aktivität eines dna-reparaturenzyms und einer krebserkrankung
US20030003454A1 (en) * 2001-03-23 2003-01-02 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer
JP3691798B2 (ja) * 2002-02-18 2005-09-07 三洋化成工業株式会社 血液中の腫瘍マーカー定量方法
US20050181375A1 (en) * 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
US20080138797A1 (en) * 2003-11-13 2008-06-12 Hunt William D Detection Systems and Methods
US7611845B2 (en) * 2004-12-17 2009-11-03 Siemens Healthcare Diagnostics Inc. Serum levels of HER2/neu as an indicator of clinical state and prognosis of prostate cancer
EP1907582B1 (de) * 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 als therapeutisches ziel für speiseröhrenkrebs
WO2008036465A2 (en) * 2006-09-18 2008-03-27 CMED Technologies Ltd. Office of Walkers Limited A method to assess cancer susceptibility and differential diagnosis of metastases of unknown primary tumors
EP2121761A1 (de) * 2007-03-09 2009-11-25 Tripath Imaging, Inc. Monoklonale he4-antikörper und ihre verwendung

Also Published As

Publication number Publication date
JP5079023B2 (ja) 2012-11-21
ES2384125T3 (es) 2012-06-29
WO2008116592A1 (en) 2008-10-02
CN101641599A (zh) 2010-02-03
EP2130048A1 (de) 2009-12-09
US20110097756A1 (en) 2011-04-28
JP2010521688A (ja) 2010-06-24
EP2130048B1 (de) 2012-04-18
CA2681577A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
WO2010136163A8 (en) Secernin-1 as a marker for cancer
ATE471512T1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
PH12018550037A1 (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
WO2014020502A3 (en) Markers associated with sensitivity to inhibitors of human double minute 2 (mdm2)
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
WO2009149319A3 (en) Gene expression profiles associated with asthma exacerbation attacks
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
KR100711046B1 (ko) 대장암에 대한 마커로서의 니코틴아미드ｎ―메틸트랜스퍼라아제의 용도
BR112015001592A8 (pt) análise de imagem e medidas de amostras biológicas
PH12017500798A1 (en) Pna probes, kits and methods for detecting human papillomavirus genotypes of human papillomavirus
BR112015019567A2 (pt) marcadores associados com inibidores de wnt
BR112014031958A2 (pt) bag3 como marcador de tecido e soro bioquímico
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
GB201014837D0 (en) Biomarker signatures and uses thereof
WO2010043393A8 (en) Use of biglycan in the assessment of heart failure
WO2010000467A8 (en) Asc as a marker for lung cancer
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
ATE531822T1 (de) Diagnose von prostatakrebs
CY1121482T1 (el) Ευαισθητη πολυπλεκτικη ανοσοδοκιμασια για τους διαλυτους υποδοχεις των αυξητικων παραγοντων των ινοβλαστων
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
DE602004001994D1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
WO2010130839A4 (en) Cybp as a marker of lung cancer